Alpha-Fetoprotein-Producing Lung Hepatoid Adenocarcinoma with Brain Metastasis Treated with S-1

Lung hepatoid adenocarcinoma (HAC) is a rare primary lung carcinoma pathologically characterized by hepatocellular carcinoma-like tumor cells, the majority of which produce alpha-fetoprotein (AFP). The clinical prognosis of lung HAC is generally poor, and effective therapeutic regimens for inoperabl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Case reports in oncology Jg. 13; H. 3; S. 1552 - 1559
Hauptverfasser: Muroyama, Yuki, Tamiya, Hiroyuki, Tanaka, Goh, Tanaka, Wakae, Huang, Alexander C., Oldridge, Derek A., Matsusaka, Keisuke, Takazawa, Yutaka, Jo, Taisuke, Ushiku, Tetsuo, Nagase, Takahide
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Basel, Switzerland S. Karger AG 01.09.2020
Karger Publishers
Schlagworte:
5-fluorouracil
alpha-fetoprotein
Antigens
Biopsy
Brain cancer
Case Report
Case reports
Chemotherapy
Cytokeratin
Edema
Embolisms
hepatoid adenocarcinoma
Liver cancer
lung
Lung cancer
Lymphatic system
Medical imaging
Medical prognosis
Metastasis
Pathology
s-1
Thrombosis
Tumors
Hepatoid adenocarcinoma
5-Fluorouracil
Lung
S-1
Alpha-fetoprotein
ISSN:1662-6575, 1662-6575
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Lung hepatoid adenocarcinoma (HAC) is a rare primary lung carcinoma pathologically characterized by hepatocellular carcinoma-like tumor cells, the majority of which produce alpha-fetoprotein (AFP). The clinical prognosis of lung HAC is generally poor, and effective therapeutic regimens for inoperable or recurrent cases have not been established. Here, we report a case of AFP-producing lung HAC with brain metastasis with long-term disease control, treated with the 5-fluorouracil-derived regimen S-1. The patient was a 66-year-old male admitted to the hospital with alexia. Chest X-ray revealed a massive tumor in the left upper lobe, and a head CT scan revealed a metastasis in the left parietal lobe. The laboratory data showed a remarkably elevated AFP level (97,561 ng/mL). Pathological assessment of the resected brain tumor revealed HAC, which was compatible with the lung biopsies. Together with the absence of other metastatic lesions, a final diagnosis of primary lung HAC, stage IV T4N3M1b, was given. The patient first underwent non-small cell lung cancer chemotherapy regimens (carboplatin and paclitaxel as the first line, and pemetrexed as the second line), but had clinical progression. After third-line oral S-1 (tegafur/gimeracil/oteracil) administration, the serum AFP level significantly dropped and the patient achieved long-term disease control without relapse, surviving more than 19 months after disease presentation. The autopsy result was consistent with the diagnosis of primary lung HAC, and immunohistochemical staining was AFP+, glypican 3+, and spalt-like transcription factor 4+. Here, we report the case of a rare primary lung HAC with apparent disease control on S-1 therapy, together with a literature review.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Report-3
ObjectType-Case Study-4
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1662-6575
1662-6575
DOI:10.1159/000511763